| 1. |
|
|
| 2. |
- Pfaller, M.A., et al.
(författare)
-
Twelve years of fluconazole in clinical practice : Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida
- 2004
-
Ingår i: Clinical Microbiology and Infection. - : Elsevier BV. - 1198-743X .- 1469-0691. ; 10:SUPPL. 1, s. 11-23
-
Tidskriftsartikel (refereegranskat)abstract
- We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for Clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI. © 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Agrell, Erik, 1965, et al.
(författare)
-
Roadmap on optical communications
- 2024
-
Ingår i: Journal of Optics. - 2040-8978 .- 2040-8986. ; 26:9
-
Forskningsöversikt (refereegranskat)abstract
- The Covid-19 pandemic showed forcefully the fundamental importance broadband data communication and the internet has in our society. Optical communications forms the undisputable backbone of this critical infrastructure, and it is supported by an interdisciplinary research community striving to improve and develop it further. Since the first ‘Roadmap of optical communications’ was published in 2016, the field has seen significant progress in all areas, and time is ripe for an update of the research status. The optical communications area has become increasingly diverse, covering research in fundamental physics and materials science, high-speed electronics and photonics, signal processing and coding, and communication systems and networks. This roadmap describes state-of-the-art and future outlooks in the optical communications field. The article is divided into 20 sections on selected areas, each written by a leading expert in that area. The sections are thematically grouped into four parts with 4-6 sections each, covering, respectively, hardware, algorithms, networks and systems. Each section describes the current status, the future challenges, and development needed to meet said challenges in their area. As a whole, this roadmap provides a comprehensive and unprecedented overview of the contemporary optical communications research, and should be essential reading for researchers at any level active in this field.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
